@nablabio: Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular pro…
Summary
Nabla Bio unveils JAM-2, a model for zero-shot drug design achieving atomic-precision, computationally designed multispecific antibodies and dual-variant KRAS multispecifics with high potency and selectivity, validated with Cryo-EM and wet-lab experiments.
View Cached Full Text
Cached at: 06/23/26, 11:55 PM
Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular proteome, and state-of-the-art atomic precision with our model, JAM-2.
In a new report (below), we show:
-
The first drug-grade, fully computationally designed multispecific antibodies against five peptide-MHCs: Routine picomolar T-cell activation/cell-killing EC50s, >100-fold selectivity, and drug-like developability
-
The first fully generatively designed, drug-grade dual-variant KRAS G12 multispecifics: They recruit primary T-cells from human donors to kill G12V and G12C presenting cells at pM to single-digit-nM potency, completely sparing wild-type.
-
Atomic accuracy, from sequence alone: Angstrom-level agreement between Cryo-EM and JAM-2 de novo designs, requiring only target sequences (not structure) as input.
-
Unrivaled speed with an AI-native in-house wet lab: Designed, built, and tested five programs in one parallelized campaign, end-to-end in-house in ~6 weeks.
-
A higher validation bar for AI-generated drug candidates: In a field increasingly rife with hype and uneven standards of proof, we provide the highest quality public wet-lab validation of AI-designed antibodies to date. We share experimental methods in full, and invite folks to adopt and build on these standards.
Truly individualized therapies will be the most important contribution of AI in drug design. These advances help accelerate this future.
Similar Articles
@SurgeBiswas: New paper from the @nablabio team expanding generative drug design to multispecifics, the intracellular proteome, and p…
Nabla Bio's new paper (JAM-2) expands generative drug design to multispecifics and the intracellular proteome, achieving zero-shot design of a KRAS G12V-targeting bispecific that recruits T cells for picomolar cell killing.
@arcinstitute: Congrats to @BrianHie, @SynBioGaoLab, and team on Germinal, now out in @NatureBiotech. Their pipeline designs epitope-t…
Arc Institute announces Germinal, a generative AI system for de novo antibody design published in Nature Biotechnology. It designs epitope-targeted antibodies with nanomolar affinity testing only tens of designs per target, making custom antibody design more accessible.
ShallowBench: Benchmarking Generative Drug Design Models on Shallow-Pocket Targets
Introduces ShallowBench, a curated benchmark of 5,780 shallow-pocket protein targets, to evaluate generative drug design models on challenging low-pocketability targets like KRAS and MYC.
The biggest AI breakthrough in medicine & drug discovery
MAML is a novel multi-modal AI model that unifies understanding of chemistry, genetics, and proteins, outperforming specialized models on 11 drug discovery benchmarks, promising to accelerate pharmaceutical research and improve success rates.
ToolMol: Evolutionary Agentic Framework for Multi-objective Drug Discovery
ToolMol is an evolutionary agentic framework that combines a multi-objective genetic algorithm with an LLM-based operator to design small-molecule drugs, achieving state-of-the-art binding affinity and drug-likeness on multiple protein targets.